[1] Addo Smith JN, Yau R, Russo HP, et al. Bacteremia in patients with liver cirrhosis: prevalence and predictors of multidrug resistant organisms. J Clin Gastroenterol,2017, 23: 1097-1108.
[2] Sarangi AN, Goel A, Singh A, et al. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration. BMC Gastroenterol, 2017, 17: 125.
[3] 中华医学会肝病学分会.慢性乙型肝炎防治指南(2015年更新版).临床肝胆病杂志,2015, 31:1941-1960.
[4] Shim JJ, Oh CH, Kim JW, et al. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy. Scand J Gastroenterol. 2017, 52: 1029-1036.
[5] Arias N, Mendez M, Alcalde I, et al. Assessing the brain through the eye: new ways to explore hepatic encephalopathy. Phvsiol Behav, 2017, 173: 263-271.
[6] Sharma BC,Singh ,J. Probiotics in management of hepatic cephalopathy. Metab Brain Dis, 2016, 31:1295-1301.
[7] Li Y,Mei L, (2iang J, et al. Magnetic resonance spectroscopy for evaluating portal-systemic encephalopathy in patients with chronic hepatic schistosomiasis japonicum. PLoS Negl Trop Dis, 2016, 10: e0005232.
[8] Moratalla A, Caparrós E, Juanola O, et al. Bifidobacterium pseudocatenulatum, CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis. J Hepatol, 2016, 64: 135-145. |
